ATE209908T1 - RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN - Google Patents

RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN

Info

Publication number
ATE209908T1
ATE209908T1 AT92914539T AT92914539T ATE209908T1 AT E209908 T1 ATE209908 T1 AT E209908T1 AT 92914539 T AT92914539 T AT 92914539T AT 92914539 T AT92914539 T AT 92914539T AT E209908 T1 ATE209908 T1 AT E209908T1
Authority
AT
Austria
Prior art keywords
disorders
derivatives
pbn
ischemia
spin
Prior art date
Application number
AT92914539T
Other languages
English (en)
Inventor
John M Carney
Robert A Floyd
Original Assignee
Oklahoma Med Res Found
Univ Kentucky Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Med Res Found, Univ Kentucky Res Found filed Critical Oklahoma Med Res Found
Application granted granted Critical
Publication of ATE209908T1 publication Critical patent/ATE209908T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT92914539T 1991-06-18 1992-06-18 RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN ATE209908T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71695291A 1991-06-18 1991-06-18
PCT/US1992/005194 WO1992022290A1 (en) 1991-06-18 1992-06-18 Use of spin trapping for the treatment of diseases associated with oxidation of lipids and proteins

Publications (1)

Publication Number Publication Date
ATE209908T1 true ATE209908T1 (de) 2001-12-15

Family

ID=24880110

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92914539T ATE209908T1 (de) 1991-06-18 1992-06-18 RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN

Country Status (5)

Country Link
EP (1) EP0590072B1 (de)
AT (1) ATE209908T1 (de)
CA (1) CA2111836C (de)
DE (1) DE69232263T2 (de)
WO (1) WO1992022290A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681845A (en) * 1989-10-17 1997-10-28 Oklahoma Medical Research Foundation DMPO spin trapping compositions and methods of use thereof
JP3167763B2 (ja) 1991-11-07 2001-05-21 株式会社ユニエ 創傷治癒促進剤
US5405967A (en) * 1993-10-22 1995-04-11 Oklahoma Medical Research Foundation Spin-trap molecules 2-trifluoromethyl- of 5,5-dimethyl-1-dyrroline-N-oxide
US5455272A (en) * 1993-10-22 1995-10-03 Oklahoma Medical Research Foundation Spin trap nitronyl hindered phenols
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
DE9408805U1 (de) * 1994-05-30 1994-09-01 Baur, Albert, 86845 Großaitingen Lautsprecher, insbesondere in Säulenform
JPH0870889A (ja) * 1994-09-02 1996-03-19 Tokyo Jiyoshi Ika Univ 臓器障害誘導因子の検出方法
DE69634647T2 (de) * 1995-09-11 2006-03-02 Aventis Pharmaceuticals Inc. Cyclische Nitrone und pharmazeutische Mittel die sie enthalten
US5972977A (en) * 1996-04-23 1999-10-26 Centaur Pharmaceuticals, Inc. Ophthalmic pharmaceutical compositions comprising a nitrone compound and methods for treating ocular inflammation using such compositions
US5900227A (en) * 1996-06-17 1999-05-04 Oklahoma Medical Research Foundation Multicyclic nitrone spin trapping compositions
EP1021430A1 (de) * 1996-07-19 2000-07-26 Centaur Pharmaceuticals, Inc. Furan-nitronverbindungen
TW429241B (en) * 1996-09-26 2001-04-11 Sumitomo Pharma Nitrone derivatives
US6096759A (en) 1997-09-19 2000-08-01 Georgetown University Method for treating essential hypertension
MA26553A1 (fr) * 1997-10-17 2004-12-20 Centaur Pharmaceuticals Inc Alpha-aryl-n-alkylnitrones et compositions pharmaceutiques contenant ceux-la
NZ505757A (en) * 1998-01-16 2002-09-27 Centaur Pharmaceuticals Inc Thioether furan nitrone compounds and pharmaceuticals thereof; useful for the treatment or prophylaxis of neurodegenerative, autoimmune and inflammatory conditions
JP2002509147A (ja) * 1998-01-16 2002-03-26 センター ファーマシューティカルズ， インコーポレイテッド チオフェンニトロン化合物
US6255353B1 (en) * 1998-03-13 2001-07-03 Centaur Pharmaceuticals, Inc. Inhibition of angiogenesis
US6194465B1 (en) 1998-05-19 2001-02-27 Centaur Pharmaceuticals, Inc. Benzamide therapeutics for the treatment of inflammatory bowel disease
CA2333190A1 (en) * 1998-05-19 1999-11-25 Beverly Greenwood-Van Meerveld Furan nitrone therapeutics for the treatment of inflammatory bowel disease
PT1077694E (pt) * 1998-05-19 2004-12-31 Renovis Inc Produtos terapeuticos de arilnitrona para o tratamento da doenca inflamatoria dointestino
US6083989A (en) 1999-05-18 2000-07-04 Centaur Pharmaceuticals, Inc. Aryl nitrone therapeutics for the treatment of inflammatory bowel disease
RU2225392C2 (ru) * 1998-06-24 2004-03-10 Реновис, Инк. Альфа-арил-N-алкилнитроны, фармацевтические композиции (варианты), способ ингибирования нейродегенеративных заболеваний, способ лечения и способы профилактики (варианты)
FR2780404B1 (fr) * 1998-06-26 2001-04-13 Adir Nouveaux derives de nitrone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2337850A1 (en) 1998-07-17 2000-01-27 Centaur Pharmaceuticals, Inc. Alpha-(2-hydroxyphenyl) nitrone compounds, pharmaceutical compositions containing the same and their use for treating inflammation
AU1917301A (en) * 1999-11-18 2001-05-30 Centaur Pharmaceuticals, Inc. Aryl nitrone therapeutics and methods for treating inflammatory bowel disease
WO2002065993A2 (en) 2001-01-08 2002-08-29 Centaur Pharmaceuticals, Inc. Use of aryl nitrone compounds in methods for treating neuropathic pain
WO2005037208A2 (en) * 2003-10-14 2005-04-28 Renovis, Inc. Nitrone compounds prodrugs and pharmaceutical compositions of the same to treat human disorders
US20080305055A1 (en) 2004-12-22 2008-12-11 Werner Baschong Anti-Radical Agents
ES2349415T3 (es) * 2004-12-22 2011-01-03 Basf Se Agentes antiradicales.
WO2007048645A2 (en) * 2005-10-24 2007-05-03 Ciba Holding Inc. Protection of oxidizable agents
FR2902097A1 (fr) * 2006-06-13 2007-12-14 Univ Joseph Fourier Etablissem Nouveau procede de preparation de nitrones et de n-hydroxylamines comportant au moins un groupe hydroxyle, et produits tels qu'obtenus
WO2008013866A2 (en) 2006-07-25 2008-01-31 Hough Ear Institute Methods for treating acute acoustic trauma
EP2242360B1 (de) * 2008-02-12 2015-04-08 Tosk, Inc. Doxorubicin-hilfsstoffe zur toxizitätsminderung und anwendungsverfahren dafür
JP6654142B2 (ja) 2014-03-07 2020-02-26 ダウ グローバル テクノロジーズ エルエルシー ニトロン化合物及びパーソナルケアにおけるその使用
CN106458871B (zh) 2014-05-12 2018-12-28 陶氏环球技术有限责任公司 硝酮化合物和其在个人护理中的用途
WO2016003767A1 (en) 2014-06-30 2016-01-07 Dow Global Technologies Llc Polymeric nitrones and their use in personal care
BR112017020038B1 (pt) 2015-03-20 2021-03-09 Dow Global Technologies Llc método para inibir a oxidação de uma gordura insaturada
US10130574B2 (en) 2015-03-20 2018-11-20 Dow Global Technologies Llc Nitrone inhibition of oxidation of unsaturated fats

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3834073A (en) * 1971-05-03 1974-09-10 Scm Corp Phenyl nitrone derivatives useful as seed protectants
US4153722A (en) * 1977-10-06 1979-05-08 William H. Rorer, Inc. Method of treatment
WO1988005044A1 (en) * 1986-12-29 1988-07-14 Pharmacia Ab Nitroxide compounds for the preparation of a pharmaceutical composition intended for the prophylaxis and treatment of ischemic cell damage
AU1362488A (en) * 1987-01-28 1988-08-24 Peter H. Proctor Topical composition and method for stimulating hair growth with stable free radicals
EP0496796B1 (de) * 1989-10-17 1994-08-31 Oklahoma Medical Research Foundation Verfahren und zubereitungen zur hemmung von mit oxidativer schädigung assoziierten krankheiten
US5036097A (en) * 1989-10-17 1991-07-30 Oklahoma Medical Research Foundation Phenylbutyl nitrone compositions and methods for prevention of gastric ulceration

Also Published As

Publication number Publication date
CA2111836A1 (en) 1992-12-23
DE69232263T2 (de) 2003-06-18
WO1992022290A1 (en) 1992-12-23
EP0590072B1 (de) 2001-12-05
EP0590072A1 (de) 1994-04-06
AU2261492A (en) 1993-01-12
AU672364B2 (en) 1996-10-03
CA2111836C (en) 2006-08-29
DE69232263D1 (de) 2002-01-17

Similar Documents

Publication Publication Date Title
DE69232263D1 (de) Radikalfänger (&#34;spin traps&#34;) zur behandlung von mit oxidation von lipiden und proteinen verbundenen erkrankungen
ATE142877T1 (de) Melatoninderivate zur behandlung von schlafstörungen und zur pre-anästhesie
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
BG101118A (en) Therapeutical compounds
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
ATE170077T1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2&#39;- halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
RU94022479A (ru) Применение антиэстрогенных соединений, а также фармацевтически приемлемых солей и сольватов для уменьшения концентрации глюкозы в крови, фармацевтический препарат
RU94041223A (ru) Средство для лечения мотонейроновых заболеваний
DE69426334D1 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
RU92016463A (ru) Применение производных цистина для изготовления лекарственных препаратов с иммуномоделирующим действием, фармацевтические композиции на их основе
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
ATE198550T1 (de) Verwendung von weihrauch zur behandlung der alzheimer-krankheit
ATE340561T1 (de) Verwendung von antiseptika zur herstellung von arzneimitteln zur prophylaxe und behandlung von entzündungen im korperinneren des menschen
DE3787477D1 (de) Nasal applizierbares Arzneimittel, Verfahren zu seiner Herstellung und seine Verwendung.
RU94040886A (ru) Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
DE58904722D1 (de) Arzneimittelzubereitung aus esterderivaten des hecogenins und dessen verwendung zur behandlung von benigner prostatahyperplasie.
NO801387L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive morfantridin-derivater
ATE316379T1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
DE69621786D1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
ATE5256T1 (de) Phenylpiperazinderivate von 1,3,4oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel.
DE68901172D1 (de) (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
DE69325512D1 (de) Verwendung von remacemid zur behandlung des morbus parkinson

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties